Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review.

Item

http://www.wikidata.org/entity/Q35805765

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Impact of switching antiretrov ...... bolic complications: a review.

@ast

Impact of switching antiretrov ...... bolic complications: a review.

@en

type

Item

label

Impact of switching antiretrov ...... bolic complications: a review.

@ast

Impact of switching antiretrov ...... bolic complications: a review.

@en

prefLabel

Impact of switching antiretrov ...... bolic complications: a review.

@ast

Impact of switching antiretrov ...... bolic complications: a review.

@en

P1476

Impact of switching antiretrov ...... bolic complications: a review.

@en

P2093

Birgitte R Hansen

http://www.w3.org/2001/XMLSchema#string

Jens Ole Nielsen

http://www.w3.org/2001/XMLSchema#string

Johan Iversen

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.

Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.

Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.

Cardiovascular risk factors in HIV-infected patients.

Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.

Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.

Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy.

Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.

Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.

P304

244-253

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/00365540410019381

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Steen Bendix Haugaard

Ove Andersen

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15198179

http://www.w3.org/2001/XMLSchema#string